Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2020
Health Canada has issued a No Objection Letter in response to IntelGenxâ€™s amended Clinical Trial Application for the ongoing Montelukast VersaFilmÂ® Phase 2a clinical trial for Alzheimerâ€™s Disease.